Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
Dafne Jacome Sanz(Tampere University), Daniela Ungureanu(Institute for Molecular Medicine Finland)
Cited by 31
Related Papers
New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome
|Cellular and Molecular Life Sciences|2022|13
Interaction between <scp>ROR</scp> 1 and Mu <scp>SK</scp> activation complex in myogenic cells
|FEBS Letters|2018|8
ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer
|Cell Death and Disease|2026|1